首页> 美国卫生研究院文献>Antimicrobial Agents and Chemotherapy >Isepamicin disposition in subjects with various degrees of renal function.
【2h】

Isepamicin disposition in subjects with various degrees of renal function.

机译:异帕米星在具有不同程度肾功能的受试者中的分布。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The disposition of isepamicin, an investigational aminoglycoside antibiotic, was evaluated in 30 subjects with various degrees of renal function. The subjects were divided into five groups: those with normal renal function (creatinine clearance [CLCR], greater than 80 ml/min/1.73 m2), those with mild renal insufficiency (CLCR, 50 to 80 ml/min/1.73 m2), those with moderate renal insufficiency (CLCR, 30 to 49 ml/min/1.73 m2), those with severe renal insufficiency (CLCR, 5 to 29 ml/min/1.73 m2), and those maintained on hemodialysis (CLCR, less than 5 ml/min/1.73 m2). Subjects on hemodialysis were studied both during hemodialysis and during an interdialytic period. The volumes of distribution of isepamicin were not significantly different among the five groups of patients. The total body clearance (CLP) and renal clearance (CLR) of isepamicin significantly decreased as CLCR decreased. The CLP of isepamicin and CLCR were significantly related [(COP = 0.391.[CLCR] + 1.83; r2 = 0.878)]. Nonrenal clearance of isepamicin did not differ between groups. Hemodialysis augmented the CLP of isepamicin by approximately 25-fold. The amount of isepamicin recovered in the dialysate was 60.6 +/- 15.8% of the dose administered. The maximal rebound of the isepamicin concentration in plasma after cessation of hemodialysis was observed at 0.78 +/- 0.7 h. Concentrations in plasma increased 32.7 +/- 22.9% over that measured at the end of hemodialysis. These data indicate that dosage adjustments are necessary in subjects with decreased renal function.
机译:在30名具有不同程度肾功能的受试者中评估了一种研究性氨基糖苷类抗生素异帕米星的配置。受试者分为五组:肾功能正常的患者(肌酐清除率[CLCR],大于80 ml / min / 1.73 m2),轻度肾功能不全的患者(CLCR,50至80 ml / min / 1.73 m2),中度肾功能不全者(CLCR,30至49 ml / min / 1.73 m2),严重肾功能不全者(CLCR,5至29 ml / min / 1.73 m2),维持血液透析的患者(CLCR,5 ml以下) /min/1.73 m2)。在血液透析期间和透析间隔期间都对接受血液透析的受试者进行了研究。在五组患者中,异帕米星的分布量没有显着差异。异帕米星的总体清除率(CLP)和肾脏清除率(CLR)随着CLCR的降低而显着降低。异帕米星和CLCR的CLP显着相关[(COP = 0.391。[CLCR] + 1.83; r2 = 0.878)]。两组之间非异帕米星的非肾脏清除率无差异。血液透析使异帕米星的CLP增加约25倍。在透析液中回收的异帕米星的量为给药剂量的60.6 +/- 15.8%。血液透析停止后,异帕米星浓度的最大反弹出现在0.78 +/- 0.7 h。与血液透析结束时相比,血浆中的浓度增加了32.7 +/- 22.9%。这些数据表明在肾功能下降的受试者中需要调整剂量。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号